nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—NR1I2—Rifampicin—leprosy	0.319	0.371	CbGbCtD
Erlotinib—SLCO2B1—Rifampicin—leprosy	0.141	0.164	CbGbCtD
Erlotinib—UGT1A1—Rifampicin—leprosy	0.105	0.122	CbGbCtD
Erlotinib—CYP1A1—Thalidomide—leprosy	0.0552	0.0641	CbGbCtD
Erlotinib—CYP3A5—Thalidomide—leprosy	0.0331	0.0385	CbGbCtD
Erlotinib—CYP3A5—Rifampicin—leprosy	0.0321	0.0373	CbGbCtD
Erlotinib—CYP2C8—Rifampicin—leprosy	0.0308	0.0358	CbGbCtD
Erlotinib—CYP3A5—Dapsone—leprosy	0.0265	0.0308	CbGbCtD
Erlotinib—CYP2C8—Dapsone—leprosy	0.0254	0.0296	CbGbCtD
Erlotinib—CYP1A2—Thalidomide—leprosy	0.0246	0.0286	CbGbCtD
Erlotinib—CYP1A2—Rifampicin—leprosy	0.0239	0.0277	CbGbCtD
Erlotinib—ABCB1—Rifampicin—leprosy	0.0209	0.0243	CbGbCtD
Erlotinib—CYP3A4—Rifampicin—leprosy	0.0125	0.0145	CbGbCtD
Erlotinib—CYP3A4—Dapsone—leprosy	0.0103	0.012	CbGbCtD
Erlotinib—Vandetanib—RIPK2—leprosy	0.00704	1	CrCbGaD
Erlotinib—Disease progression—Thalidomide—leprosy	0.00516	0.0572	CcSEcCtD
Erlotinib—Gastrointestinal perforation—Thalidomide—leprosy	0.00432	0.0479	CcSEcCtD
Erlotinib—Intestinal perforation—Thalidomide—leprosy	0.00285	0.0316	CcSEcCtD
Erlotinib—Proteinuria—Dapsone—leprosy	0.00251	0.0278	CcSEcCtD
Erlotinib—Protein urine present—Dapsone—leprosy	0.00247	0.0274	CcSEcCtD
Erlotinib—Skin exfoliation—Dapsone—leprosy	0.0021	0.0233	CcSEcCtD
Erlotinib—Foetor hepaticus—Thalidomide—leprosy	0.00199	0.022	CcSEcCtD
Erlotinib—Deep vein thrombosis—Thalidomide—leprosy	0.00185	0.0205	CcSEcCtD
Erlotinib—Nail disorder—Thalidomide—leprosy	0.00174	0.0193	CcSEcCtD
Erlotinib—Liver disorder—Thalidomide—leprosy	0.00165	0.0183	CcSEcCtD
Erlotinib—Interstitial lung disease—Thalidomide—leprosy	0.00159	0.0177	CcSEcCtD
Erlotinib—Lung disorder—Thalidomide—leprosy	0.00159	0.0177	CcSEcCtD
Erlotinib—AURKC—tendon—leprosy	0.00142	0.0334	CbGeAlD
Erlotinib—Rash pustular—Thalidomide—leprosy	0.00141	0.0157	CcSEcCtD
Erlotinib—HIPK4—testis—leprosy	0.00138	0.0324	CbGeAlD
Erlotinib—LTK—testis—leprosy	0.00136	0.032	CbGeAlD
Erlotinib—Pancreatitis—Dapsone—leprosy	0.00135	0.015	CcSEcCtD
Erlotinib—ULK3—eye—leprosy	0.00135	0.0317	CbGeAlD
Erlotinib—Acne—Thalidomide—leprosy	0.00134	0.0149	CcSEcCtD
Erlotinib—Proteinuria—Thalidomide—leprosy	0.00128	0.0142	CcSEcCtD
Erlotinib—MKNK1—eye—leprosy	0.00127	0.0299	CbGeAlD
Erlotinib—Protein urine present—Thalidomide—leprosy	0.00127	0.014	CcSEcCtD
Erlotinib—Cellulitis—Thalidomide—leprosy	0.00124	0.0137	CcSEcCtD
Erlotinib—Drug interaction—Thalidomide—leprosy	0.00122	0.0135	CcSEcCtD
Erlotinib—CYP1A1—skin epidermis—leprosy	0.00121	0.0285	CbGeAlD
Erlotinib—Neuropathy peripheral—Dapsone—leprosy	0.00121	0.0134	CcSEcCtD
Erlotinib—TNK1—tendon—leprosy	0.00121	0.0284	CbGeAlD
Erlotinib—Bone pain—Thalidomide—leprosy	0.00118	0.013	CcSEcCtD
Erlotinib—AURKC—testis—leprosy	0.00117	0.0276	CbGeAlD
Erlotinib—AURKC—nervous system—leprosy	0.00115	0.0271	CbGeAlD
Erlotinib—Hepatocellular injury—Thalidomide—leprosy	0.00113	0.0125	CcSEcCtD
Erlotinib—EPHA6—testis—leprosy	0.00109	0.0256	CbGeAlD
Erlotinib—JAK3—testis—leprosy	0.00109	0.0256	CbGeAlD
Erlotinib—Colitis—Thalidomide—leprosy	0.00108	0.012	CcSEcCtD
Erlotinib—Skin exfoliation—Thalidomide—leprosy	0.00108	0.0119	CcSEcCtD
Erlotinib—JAK3—nervous system—leprosy	0.00107	0.0251	CbGeAlD
Erlotinib—EPHA6—nervous system—leprosy	0.00107	0.0251	CbGeAlD
Erlotinib—Neuropathy—Thalidomide—leprosy	0.00106	0.0117	CcSEcCtD
Erlotinib—Dry eye—Thalidomide—leprosy	0.00104	0.0115	CcSEcCtD
Erlotinib—TNK1—testis—leprosy	0.000999	0.0235	CbGeAlD
Erlotinib—ABL2—tendon—leprosy	0.000989	0.0233	CbGeAlD
Erlotinib—MAP3K19—testis—leprosy	0.000989	0.0232	CbGeAlD
Erlotinib—Sepsis—Thalidomide—leprosy	0.000978	0.0108	CcSEcCtD
Erlotinib—MAP3K19—nervous system—leprosy	0.00097	0.0228	CbGeAlD
Erlotinib—Erythema—Dapsone—leprosy	0.000963	0.0107	CcSEcCtD
Erlotinib—PIP4K2C—tendon—leprosy	0.000936	0.022	CbGeAlD
Erlotinib—ULK3—tendon—leprosy	0.000894	0.021	CbGeAlD
Erlotinib—Renal failure acute—Thalidomide—leprosy	0.000887	0.00983	CcSEcCtD
Erlotinib—FLT3—testis—leprosy	0.000858	0.0202	CbGeAlD
Erlotinib—Dermatitis bullous—Thalidomide—leprosy	0.000856	0.00949	CcSEcCtD
Erlotinib—Cough—Dapsone—leprosy	0.00084	0.00931	CcSEcCtD
Erlotinib—Cerebrovascular accident—Thalidomide—leprosy	0.000835	0.00926	CcSEcCtD
Erlotinib—ABL2—testis—leprosy	0.000819	0.0193	CbGeAlD
Erlotinib—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000818	0.00907	CcSEcCtD
Erlotinib—EGFR—testis—leprosy	0.0008	0.0188	CbGeAlD
Erlotinib—SLK—tendon—leprosy	0.000797	0.0187	CbGeAlD
Erlotinib—PIP4K2C—testis—leprosy	0.000775	0.0182	CbGeAlD
Erlotinib—Dehydration—Thalidomide—leprosy	0.000761	0.00844	CcSEcCtD
Erlotinib—PIP4K2C—nervous system—leprosy	0.000761	0.0179	CbGeAlD
Erlotinib—Dry skin—Thalidomide—leprosy	0.00075	0.00832	CcSEcCtD
Erlotinib—Hypokalaemia—Thalidomide—leprosy	0.000745	0.00826	CcSEcCtD
Erlotinib—ULK3—testis—leprosy	0.00074	0.0174	CbGeAlD
Erlotinib—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000737	0.00817	CcSEcCtD
Erlotinib—ULK3—nervous system—leprosy	0.000726	0.0171	CbGeAlD
Erlotinib—Alanine aminotransferase increased—Thalidomide—leprosy	0.000722	0.008	CcSEcCtD
Erlotinib—ABL1—eye—leprosy	0.000721	0.0169	CbGeAlD
Erlotinib—Insomnia—Dapsone—leprosy	0.000711	0.00788	CcSEcCtD
Erlotinib—Dysphagia—Thalidomide—leprosy	0.000707	0.00784	CcSEcCtD
Erlotinib—MKNK1—testis—leprosy	0.000697	0.0164	CbGeAlD
Erlotinib—Pancreatitis—Thalidomide—leprosy	0.000694	0.00769	CcSEcCtD
Erlotinib—STK10—tendon—leprosy	0.000693	0.0163	CbGeAlD
Erlotinib—MKNK1—nervous system—leprosy	0.000684	0.0161	CbGeAlD
Erlotinib—Neutropenia—Thalidomide—leprosy	0.000661	0.00733	CcSEcCtD
Erlotinib—SLK—testis—leprosy	0.00066	0.0155	CbGeAlD
Erlotinib—Gastrointestinal pain—Dapsone—leprosy	0.000643	0.00712	CcSEcCtD
Erlotinib—Weight decreased—Thalidomide—leprosy	0.00064	0.00709	CcSEcCtD
Erlotinib—Pneumonia—Thalidomide—leprosy	0.000634	0.00703	CcSEcCtD
Erlotinib—Infestation—Thalidomide—leprosy	0.000631	0.00699	CcSEcCtD
Erlotinib—Infestation NOS—Thalidomide—leprosy	0.000631	0.00699	CcSEcCtD
Erlotinib—Depression—Thalidomide—leprosy	0.000629	0.00697	CcSEcCtD
Erlotinib—ABL1—skin of body—leprosy	0.000627	0.0147	CbGeAlD
Erlotinib—Stevens-Johnson syndrome—Thalidomide—leprosy	0.000625	0.00693	CcSEcCtD
Erlotinib—Acute coronary syndrome—Thalidomide—leprosy	0.000622	0.00689	CcSEcCtD
Erlotinib—Body temperature increased—Dapsone—leprosy	0.000621	0.00689	CcSEcCtD
Erlotinib—Abdominal pain—Dapsone—leprosy	0.000621	0.00689	CcSEcCtD
Erlotinib—Renal failure—Thalidomide—leprosy	0.00062	0.00687	CcSEcCtD
Erlotinib—MAP2K5—tendon—leprosy	0.000619	0.0145	CbGeAlD
Erlotinib—Myocardial infarction—Thalidomide—leprosy	0.000618	0.00685	CcSEcCtD
Erlotinib—Neuropathy peripheral—Thalidomide—leprosy	0.000618	0.00685	CcSEcCtD
Erlotinib—Stomatitis—Thalidomide—leprosy	0.000615	0.00681	CcSEcCtD
Erlotinib—Conjunctivitis—Thalidomide—leprosy	0.000613	0.0068	CcSEcCtD
Erlotinib—CYP1B1—eye—leprosy	0.00061	0.0143	CbGeAlD
Erlotinib—Epistaxis—Thalidomide—leprosy	0.000595	0.00659	CcSEcCtD
Erlotinib—STK10—testis—leprosy	0.000574	0.0135	CbGeAlD
Erlotinib—Hepatitis—Thalidomide—leprosy	0.000566	0.00628	CcSEcCtD
Erlotinib—STK10—nervous system—leprosy	0.000563	0.0132	CbGeAlD
Erlotinib—Urinary tract disorder—Thalidomide—leprosy	0.000559	0.0062	CcSEcCtD
Erlotinib—Urethral disorder—Thalidomide—leprosy	0.000555	0.00615	CcSEcCtD
Erlotinib—Erythema multiforme—Thalidomide—leprosy	0.000535	0.00593	CcSEcCtD
Erlotinib—CYP1B1—skin of body—leprosy	0.000531	0.0125	CbGeAlD
Erlotinib—Eye disorder—Thalidomide—leprosy	0.000529	0.00587	CcSEcCtD
Erlotinib—MAP2K5—testis—leprosy	0.000512	0.012	CbGeAlD
Erlotinib—Mediastinal disorder—Thalidomide—leprosy	0.00051	0.00566	CcSEcCtD
Erlotinib—Chills—Thalidomide—leprosy	0.000508	0.00563	CcSEcCtD
Erlotinib—Arrhythmia—Thalidomide—leprosy	0.000506	0.00561	CcSEcCtD
Erlotinib—MAP2K5—nervous system—leprosy	0.000503	0.0118	CbGeAlD
Erlotinib—Alopecia—Thalidomide—leprosy	0.0005	0.00555	CcSEcCtD
Erlotinib—Vomiting—Dapsone—leprosy	0.0005	0.00554	CcSEcCtD
Erlotinib—Mental disorder—Thalidomide—leprosy	0.000496	0.0055	CcSEcCtD
Erlotinib—Malnutrition—Thalidomide—leprosy	0.000493	0.00546	CcSEcCtD
Erlotinib—Headache—Dapsone—leprosy	0.000492	0.00546	CcSEcCtD
Erlotinib—Flatulence—Thalidomide—leprosy	0.000486	0.00538	CcSEcCtD
Erlotinib—SLCO2B1—tendon—leprosy	0.000481	0.0113	CbGeAlD
Erlotinib—ABL1—tendon—leprosy	0.000477	0.0112	CbGeAlD
Erlotinib—Back pain—Thalidomide—leprosy	0.000477	0.00528	CcSEcCtD
Erlotinib—Nausea—Dapsone—leprosy	0.000467	0.00517	CcSEcCtD
Erlotinib—Syncope—Thalidomide—leprosy	0.000442	0.0049	CcSEcCtD
Erlotinib—Loss of consciousness—Thalidomide—leprosy	0.000433	0.0048	CcSEcCtD
Erlotinib—Cough—Thalidomide—leprosy	0.00043	0.00477	CcSEcCtD
Erlotinib—ABCB1—blood vessel—leprosy	0.000421	0.0099	CbGeAlD
Erlotinib—Chest pain—Thalidomide—leprosy	0.00042	0.00465	CcSEcCtD
Erlotinib—Arthralgia—Thalidomide—leprosy	0.00042	0.00465	CcSEcCtD
Erlotinib—Myalgia—Thalidomide—leprosy	0.00042	0.00465	CcSEcCtD
Erlotinib—Anxiety—Thalidomide—leprosy	0.000418	0.00464	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000417	0.00462	CcSEcCtD
Erlotinib—ORM1—nervous system—leprosy	0.000408	0.0096	CbGeAlD
Erlotinib—CYP1B1—tendon—leprosy	0.000404	0.0095	CbGeAlD
Erlotinib—Oedema—Thalidomide—leprosy	0.000402	0.00446	CcSEcCtD
Erlotinib—Infection—Thalidomide—leprosy	0.0004	0.00443	CcSEcCtD
Erlotinib—SLCO2B1—testis—leprosy	0.000399	0.00937	CbGeAlD
Erlotinib—Shock—Thalidomide—leprosy	0.000396	0.00439	CcSEcCtD
Erlotinib—ABL1—testis—leprosy	0.000395	0.00929	CbGeAlD
Erlotinib—Nervous system disorder—Thalidomide—leprosy	0.000394	0.00437	CcSEcCtD
Erlotinib—Thrombocytopenia—Thalidomide—leprosy	0.000394	0.00437	CcSEcCtD
Erlotinib—SLCO2B1—nervous system—leprosy	0.000391	0.0092	CbGeAlD
Erlotinib—Skin disorder—Thalidomide—leprosy	0.000391	0.00433	CcSEcCtD
Erlotinib—ABL1—nervous system—leprosy	0.000388	0.00912	CbGeAlD
Erlotinib—Anorexia—Thalidomide—leprosy	0.000383	0.00425	CcSEcCtD
Erlotinib—CYP1A1—skin of body—leprosy	0.000375	0.00882	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Thalidomide—leprosy	0.000367	0.00406	CcSEcCtD
Erlotinib—ALB—testis—leprosy	0.000365	0.00857	CbGeAlD
Erlotinib—Insomnia—Thalidomide—leprosy	0.000364	0.00403	CcSEcCtD
Erlotinib—Dyspnoea—Thalidomide—leprosy	0.000359	0.00398	CcSEcCtD
Erlotinib—Dyspepsia—Thalidomide—leprosy	0.000354	0.00393	CcSEcCtD
Erlotinib—Decreased appetite—Thalidomide—leprosy	0.00035	0.00388	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Thalidomide—leprosy	0.000347	0.00385	CcSEcCtD
Erlotinib—Fatigue—Thalidomide—leprosy	0.000347	0.00384	CcSEcCtD
Erlotinib—Constipation—Thalidomide—leprosy	0.000344	0.00381	CcSEcCtD
Erlotinib—Pain—Thalidomide—leprosy	0.000344	0.00381	CcSEcCtD
Erlotinib—CYP1B1—testis—leprosy	0.000335	0.00787	CbGeAlD
Erlotinib—Gastrointestinal pain—Thalidomide—leprosy	0.000329	0.00365	CcSEcCtD
Erlotinib—CYP1B1—nervous system—leprosy	0.000328	0.00772	CbGeAlD
Erlotinib—Abdominal pain—Thalidomide—leprosy	0.000318	0.00352	CcSEcCtD
Erlotinib—Body temperature increased—Thalidomide—leprosy	0.000318	0.00352	CcSEcCtD
Erlotinib—Asthenia—Thalidomide—leprosy	0.000289	0.0032	CcSEcCtD
Erlotinib—Pruritus—Thalidomide—leprosy	0.000285	0.00315	CcSEcCtD
Erlotinib—Diarrhoea—Thalidomide—leprosy	0.000275	0.00305	CcSEcCtD
Erlotinib—Dizziness—Thalidomide—leprosy	0.000266	0.00295	CcSEcCtD
Erlotinib—CYP2C8—testis—leprosy	0.000256	0.00603	CbGeAlD
Erlotinib—Vomiting—Thalidomide—leprosy	0.000256	0.00284	CcSEcCtD
Erlotinib—Rash—Thalidomide—leprosy	0.000254	0.00281	CcSEcCtD
Erlotinib—Dermatitis—Thalidomide—leprosy	0.000253	0.00281	CcSEcCtD
Erlotinib—Headache—Thalidomide—leprosy	0.000252	0.00279	CcSEcCtD
Erlotinib—ABCG2—testis—leprosy	0.000249	0.00586	CbGeAlD
Erlotinib—Nausea—Thalidomide—leprosy	0.000239	0.00265	CcSEcCtD
Erlotinib—CYP1A1—nervous system—leprosy	0.000232	0.00546	CbGeAlD
Erlotinib—CYP2D6—testis—leprosy	0.000171	0.00402	CbGeAlD
Erlotinib—CYP3A4—nervous system—leprosy	0.00017	0.00401	CbGeAlD
Erlotinib—CYP2D6—nervous system—leprosy	0.000168	0.00394	CbGeAlD
Erlotinib—ABCB1—testis—leprosy	0.000123	0.00289	CbGeAlD
Erlotinib—ABCB1—nervous system—leprosy	0.000121	0.00284	CbGeAlD
